Literature DB >> 3606080

Penetration of cefotaxime into respiratory secretions.

R B Fick, M R Alexander, R A Prince, J E Kasik.   

Abstract

The objective of this study was to quantitate cefotaxime and its active metabolite, desacetyl cefotaxime, in the distal airways and to compare these levels to concentrations in plasma. Respiratory secretions were obtained from the subsegmental level in 17 adult patients undergoing fiber-optic bronchoscopy within 2 h after receiving four doses of cefotaxime (2 g intravenously every 6 h). In 11 patients, cefotaxime levels measured by high-pressure liquid chromatography in bronchial secretions were below detectable limits (less than 0.5 mg/liter); however, levels of desacetyl cefotaxime exceeded 1.5 mg/liter in 9 of these 11 patients (range, 1.6 to 10 mg/liter). Concentrations of desacetyl cefotaxime in lung secretions (6.9 +/- 0.85 [standard error] mg/liter) was 77% of mean levels of desacetyl cefotaxime in plasma (8.9 +/- 1.26 mg/liter). In summary, concentrations of desacetyl cefotaxime in bronchial secretions are markedly higher than those of cefotaxime.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3606080      PMCID: PMC174841          DOI: 10.1128/AAC.31.5.815

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Cefotaxime metabolism by hemolyzed blood: quantitation and inhibition of the deacetylation reaction.

Authors:  W D Welch; R E Bawdon
Journal:  Diagn Microbiol Infect Dis       Date:  1986-02       Impact factor: 2.803

2.  Cefotaxime in bronchopulmonary infections--a clinical and pharmacological study.

Authors:  H Lode; B Kemmerich; G Gruhlke; G Dzwillo; P Koeppe; I Wagner
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

3.  Bronchial secretion concentrations of tobramycin.

Authors:  M R Alexander; J Schoell; G Hicklin; J E Kasik; D Coleman
Journal:  Am Rev Respir Dis       Date:  1982-02

Review 4.  The aerobic gram-negative bacillary pneumonias.

Authors:  M P Reyes
Journal:  Med Clin North Am       Date:  1980-05       Impact factor: 5.456

5.  Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis.

Authors:  R B Fick; G P Naegel; S U Squier; R E Wood; J B Gee; H Y Reynolds
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

6.  Bronchial secretion levels of amikacin.

Authors:  W L Dull; M R Alexander; J E Kasik
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

7.  Clinical pharmacokinetics of cefotaxime and penetration in sputum, bone, and prostatic tissue.

Authors:  P C Braga; C Pozzato; C Cedrini; F Fraschini; G Scarpazza; F Scaglione; V Gagliardi; F Apicella; V Manganelli; G Paiola
Journal:  Clin Ther       Date:  1982       Impact factor: 3.393

8.  Penetration of cefotaxime into bronchial secretions.

Authors:  E Bergogne-Berezin; C Morel; J Pierre; N Monrocq; P Dournovo; Y Benard
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct

9.  Antimicrobial activity of desacetylcefotaxime alone and in combination with cefotaxime: evidence of synergy.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct

10.  Activity of the cefotaxime (HR756) desacetyl metabolite compared with those of cefotaxime and other cephalosporins.

Authors:  R Wise; P J Wills; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1980-01       Impact factor: 5.191

  10 in total
  2 in total

Review 1.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

Review 2.  Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.

Authors:  R N Brogden; C M Spencer
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.